Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

RHEUMATOID ARTHRITIS

DMARDs for mental health symptoms in RA

Nature Reviews Rheumatology volume 14, pages 507–508 (2018)Cite this article

Subjects

Mental health symptoms are a common and functionally impairing feature of rheumatoid arthritis, and increasingly seem to represent an integral part of the inflammatory process. Could treatment with DMARDs affect physical as well as mental health outcomes?

Refers to Matcham, F. et al. The impact of targeted rheumatoid arthritis pharmacological treatment on mental health: a systematic review and network meta-analysis. Arthritis Rheumatol. https://doi.org/10.1002/art.40565 (2018).

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Savitz, J. & Harrison, N. A. Interoception and inflammation in psychiatric disorders. Biol. Psychiatry Cogn. Neurosci. Neuroimag. 3, 514–552 (2018).

    Google Scholar 

  2. Bullmore, E. The inflamed mind: A radical new approach to depression. (Short Books, London, 2018).

    Google Scholar 

  3. Matcham, F. et al. The impact of targeted rheumatoid arthritis pharmacological treatment on mental health: a systematic review and network meta-analysis. Arthritis Rheumatol. https://doi.org/10.1002/art.40565 (2018).

    PubMed  Article  Google Scholar 

  4. Matcham, F. et al. Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet. Disord. 17, 224 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Anderson, I. M. et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J. Psychopharm. 22, 343–396 (2008).

    Article  CAS  Google Scholar 

  6. Turner, E. H. et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358, 252–260 (2008).

    Article  PubMed  CAS  Google Scholar 

  7. Tugwell, P. et al. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 26, 38 (2007).

    Article  Google Scholar 

  8. Harrison, N. A. in Inflammation-Associated Depression: Evidence, Mechanisms and Implications (eds Dantzer, R. & Capuron, L.) 221–248 (Springer International, 2017).

  9. Haapakoski, R. et al. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun. 49, 206–215 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Miller, B. J. & Buckley, P. F. Monoclonal antibody immunotherapy in psychiatric disorders. Lancet Psychiatry 4, 13–15 (2017).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

N.A.H. is in receipt of grant funding from the Wellcome Trust, the UK Medical Research Council, Arthritis Research UK (ARUK), Action for ME and Janssen pharmaceuticals. K.D. is in receipt of financial support from ARUK.

Author information

Affiliations

  1. Department of Neuroscience, Brighton and Sussex Medical School, University of Sussex, Brighton, UK

    Neil A. Harrison

  2. Sussex Partnership NHS Foundation Trust, Swandean, UK

    Neil A. Harrison

  3. Department of Medicine, Brighton and Sussex Medical School, University of Sussex, Brighton, UK

    Kevin Davies

  4. Department of Rheumatology, Brighton and Sussex University Hospitals Trust, Brighton, UK

    Kevin Davies

Authors
  1. Neil A. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil A. Harrison.

Ethics declarations

Competing interests

N.A.H. declares that he receives research funding support from Janssen pharmaceuticals and has acted as a paid consultant for GSK. K.D. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Harrison, N.A., Davies, K. DMARDs for mental health symptoms in RA. Nat Rev Rheumatol 14, 507–508 (2018). https://doi.org/10.1038/s41584-018-0063-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-018-0063-z

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing